In a promising development for public health, early figures from the Centers for Disease Control and Prevention (CDC) show that diabetes deaths in the United States have dropped to their lowest levels in years. This decline follows a troubling surge during the COVID-19 pandemic, when diabetes-related mortality reached a peak not seen in recent history. According to preliminary data from the CDC's National Center for Health Statistics, the death rate from diabetes fell to 26.4 per 100,000 people in the third quarter of 2024. This marks a significant improvement from the 2021 peak of 31.1 per 100,000, when diabetes was ranked as the eighth leading cause of death in the country.

These encouraging numbers suggest a partial rebound from the pandemic’s devastating impact on individuals with chronic conditions. The CDC attributes the earlier increase in mortality to the intersection of COVID-19 and diabetes, a combination that proved particularly dangerous. Christopher Holliday, director of the CDC’s Division of Diabetes Translation, emphasized that people with underlying conditions like diabetes were more likely to experience severe illness from COVID-19, often leading to hospitalization or death. He also noted that the pandemic disrupted many aspects of disease management, from physical activity routines to access to routine medical care, further complicating care for those living with diabetes.

Despite the recent decline in deaths, Holliday cautioned that diabetes-related mortality has not yet returned to pre-pandemic levels. In 2019, before the onset of COVID-19, there were 87,647 recorded deaths from diabetes. That number rose sharply to 103,294 in 2021, representing a more than 17% increase. By comparison, provisional data for 2024 show a total of 94,294 diabetes deaths, indicating a downward trend that, while heartening, still falls short of earlier baselines.

One notable aspect of this trend is that it comes at a time when the prevalence of diabetes continues to rise. According to the CDC’s National Health Interview Survey, nearly 1 in 10 adults in the U.S. had diagnosed diabetes in 2023. This makes the decline in death rates particularly significant, as it suggests that despite more people living with the disease, outcomes are improving. I found this detail striking, as it points to the potential impact of better disease management and medical advancements.

Indeed, the years since the pandemic have seen the introduction and growing use of new diabetes treatments, such as Ozempic and Mounjaro. These medications have garnered widespread attention and demand, offering additional tools for managing blood sugar levels and potentially contributing to improved patient outcomes. While the CDC data does not directly link these treatments to the decline in mortality, their growing role in diabetes care is an important part of the broader context.

Experts urge caution, however, when interpreting long-term trends in diabetes deaths. Elizabeth Selvin, director of the Johns Hopkins Welch Center for Prevention, Epidemiology and Clinical Research, explained that changes in how diabetes is defined and recorded over time can affect the data. For instance, not all death certificates list diabetes as the primary cause of death. In many cases, it is recorded as a contributing factor, particularly in deaths from cardiovascular disease, which is common among people with diabetes.

Selvin noted that the decision of whether to list diabetes or another condition as the cause of death often depends on the physician completing the death certificate. As a result, trends in reported causes of death may reflect not only actual changes in health outcomes but also shifts in medical awareness and documentation practices. This complexity highlights the importance of looking at the broader picture when assessing public health data.

Nonetheless, the recent reduction in diabetes mortality offers a hopeful sign that the healthcare system is regaining its footing after the upheaval of the pandemic. The decline may reflect improved access to care, increased public awareness, and the benefits of new treatments. It also underscores the resilience of individuals managing chronic conditions under challenging circumstances.

While the road to fully reversing the pandemic’s impact on diabetes-related deaths remains long, these early figures suggest progress. Continued investment in public health infrastructure, equitable access to treatment, and ongoing research will be essential in sustaining and accelerating these gains. As the CDC and other health organizations continue to monitor these trends, the data will play a critical role in shaping future strategies for diabetes prevention and care.

For now, the drop in diabetes death rates provides a moment of cautious optimism. It serves as a reminder of the importance of comprehensive healthcare, the value of medical innovation, and the need for sustained attention to chronic disease management in a post-pandemic world.

Read more at cbsnews.com